Literature DB >> 2480944

The tumor rejection antigen separated from Rous sarcoma virus-induced murine fibrosarcoma exhibits a molecular weight of approximately 60 kD but differs from functional pp60src.

T Suda1, J Shimizu, M Muramatsu, K Kimura, T O Yoshida, Y Fukami, H Fujiwara, T Hamaoka.   

Abstract

The tumor antigen capable of inducing tumor resistance (tumor rejection antigen; TRA) was obtained in a solubilized form by sodium dodecyl sulfate (SDS) extraction of plasma membrane fraction from Rous sarcoma virus (RSV)-induced CSA1M fibrosarcoma cells (BALB/c origin). Analyses by Sephacryl S-300 gel filtration and SDS-polyacrylamide gel electrophoresis revealed that TRA activity was recovered in the fraction with a molecular weight of approximately 60 kD. Unfractionated crude SDS-solubilized preparation contained gp70 as detected by rabbit anti-gp70 antiserum, whereas such reactivity was lost in the fraction exhibiting the molecular weight of about 60 kD. Since this fraction retained pp60src activity, the relation of TRA to pp60src was further investigated. pp60v-src was also obtained from the lysate of v-src-expressing yeast transformant. Immunization of BALB/c mice with such pp60v-src-containing lysate failed to induce any significant tumor protection. The above 60 kD fraction of CSA1M solubilized antigens was allowed to bind to Sepharose beads coupled with anti-pp60src monoclonal antibody and separated into the bead-bound and bead-unbound fractions. The bead-bound fraction that was recovered from pp60src-binding beads (pp60src-positive fraction) did not exhibit the TRA activity. In contrast, immunization with the fraction depleted of pp60src activity (bead-unbound fraction) resulted in potent tumor protection. These results indicate that the solubilized membranous component(s) of CSA1M with a molecular weight of approximately 60 kD, which is distinct from functional pp60src, functions as the TRA against RSV-induced CSA1M tumor cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2480944      PMCID: PMC5917855          DOI: 10.1111/j.1349-7006.1989.tb01730.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  24 in total

Review 1.  Cell-surface antigens induced by RNA tumour viruses.

Authors:  R Kurth; E M Fenyö; E Klein; M Essex
Journal:  Nature       Date:  1979-05-17       Impact factor: 49.962

2.  Protein kinase activity associated with the avian sarcoma virus src gene product.

Authors:  M S Collett; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

3.  Purification of the Rous sarcoma virus src kinase by casein-agarose and tyrosine-agarose affinity chromatography.

Authors:  Y Fukami; F Lipmann
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

4.  Radioreceptor assay for growth hormone.

Authors:  T Tsushima; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

Review 5.  Virion and tumor cell antigens of C-type rna tumor viruses.

Authors:  H Bauer
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Gene product of v-fgr onc: hybrid protein containing a portion of actin and a tyrosine-specific protein kinase.

Authors:  G Naharro; K C Robbins; E P Reddy
Journal:  Science       Date:  1984-01-06       Impact factor: 47.728

8.  Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo.

Authors:  F Plata; P Langlade-Demoyen; J P Abastado; T Berbar; P Kourilsky
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

9.  Gel filtration in sodium dodecyl sulphate of hydrophobic muscle proteins on Sephacryl S-400 Superfine.

Authors:  V V Schreurs; H A Boekholt; R E Koopmanschap
Journal:  J Chromatogr       Date:  1983-01-07

10.  Antigenic determinants in a virus-induced mouse mammary tumor recognized by cell-mediated immune assays.

Authors:  P F Lopez; W P Parks; D M Lopez
Journal:  J Natl Cancer Inst       Date:  1984-03       Impact factor: 13.506

View more
  1 in total

1.  Tumor immunity generated in the course of regression of v-src-induced sarcomas.

Authors:  T W Wisner; J M England; D Y Pan; A W Stoker; M S Halpern
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.